Managing cardiotoxicity in anthracycline-treated breast cancers

Princess Margaret Hospital, Department of Medical Oncology, Toronto, Canada.
Expert Opinion on Drug Safety (Impact Factor: 2.91). 06/2007; 6(3):315-21. DOI: 10.1517/14740338.6.3.315
Source: PubMed


Anthracyclines are among the most active chemotherapeutic agents in cancer treatment. Although infrequent, cumulative dose-dependent cardiotoxicity is nevertheless a significant side effect of this therapy resulting in reduced cardiac reserve or even frank cardiac failure. Although used in several types of malignancy, anthracyclines are most commonly used in breast cancer treatment. Importantly, recent advances have also seen the increasing use of another cardiotoxic agent, the monoclonal antibody trastuzumab, both in the metastatic as well as in the adjuvant breast cancer setting. This review discusses the relationship of cardiotoxicity and anthracycline use, particularly in the breast cancer setting, and explores available treatment options for the anthracycline-treated patients based on evidence from recent Phase III trials.

6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ten million cancer survivors in the United States are at increased risk for developing late effects of treatment. Due to a lack of consistent follow-up care, many long-term cancer survivors use the Internet as a source of information and support. Research on online support for this cohort is lacking. The purposes of this study were to identify major themes related to long-term cancer survivorship and report late effects of treatment as described by members of an online support group. A qualitative descriptive method was utilized. Seventy-five long-term cancer survivors posted 300 messages online during an 8-week period and reported a wide variety of late effects. Three categorical schemes were identified: information exchange, symptomatology, and frustration with healthcare providers. Cancer survivors are utilizing Internet resources to find health-related information and support that has not been provided by healthcare providers. Additional research is needed to generate knowledge about the role of online support for long-term cancer survivors.
    CIN Computers Informatics Nursing 01/2008; 26(1):49-58. DOI:10.1097/01.NCN.0000304753.41493.f4 · 0.72 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate whether technetium 99m hydrazinonicotinamide (99mTc-HYNIC)-annexin V single-photon emission computed tomography (SPECT) would detect dose-dependent doxorubicin (DOX)-mediated cell death in the heart compared with functional echocardiography. Adult female Sprague-Dawley rats were treated with DOX (cumulative dose of 15 or 7.5 mg/kg) or saline (n = 7) and monitored by echocardiography. Rats were injected with 7 to 8 mCi 99mTc-HYNIC-annexin V and imaged 1 hour postinjection using a small animal dual-head SPECT/computed tomography (CT) system with multipinhole technology. Two regions of interest were drawn in the myocardium and soft tissue regions to calculate the cardiac uptake ratio (CUR) of reconstructed images. Myocardium and blood were harvested for radioactivity measurements or TUNEL assay. Biodistribution of 99mTc-HYNIC-annexin V uptake, CUR from SPECT/CT fused cardiac images, and TUNEL of myocardium demonstrated a dose-dependent toxicity response, with the cumulative 15 mg/kg DOX treatment showing the greatest degree of cell death. In contrast, echocardiography detected functional deficits only at the highest DOX dose. In vivo molecular imaging of DOX-induced cardiac toxicity with 99mTc-HYNIC-annexin V detects dose-dependent cell death before ventricular deficits are observed with echocardiography. 99mTc-HYNIC-annexin V SPECT-based molecular imaging may provide an attractive new technique for assessing early changes in myocardial function in patients undergoing DOX therapy.
    Molecular Imaging 05/2008; 7(3):132-8. DOI:10.2310/7290.2008.00015 · 1.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although rare, cardiotoxicity is a significant complication of cancer treatment. The incidence and severity of cardiovascular side effects are dependent on the type of drugs used, dose and schedule employed, and age of patients, as well as the presence of coexisting cardiac diseases and previous mediastinal irradiation. Classically, anthracyclines are among one of the most active agents in oncology, but their use is often hampered by their cumulative dose-limiting cardiotoxicity. In the past decade, combination therapy with new drugs such as taxanes or anti- EGFR, and Her-2 therapy as a single agent have also resulted in unexpected cardiotoxicity. Cardiac damage can be secondary to an alteration of cardiac rhythm, changes in blood pressure and ischaemia, and can also alter the ability of the heart to contract and/or relax. The clinical spectrum of these toxicities can range from subclinical abnormalities to being catastrophic, life-threatening and sometimes fatal. Knowledge of this toxicity can aid clinicians to choose the optimal and least toxic regimen suitable for an individual patient. In this work we present an exhaustive review of the cardiovascular side effects associated to new anticancer drugs, from new formulations of anthracyclines to tyrosine kinase inhibitors and monoclonal antibodies.
    Clinical and Translational Oncology 02/2008; 10(1):35-46. DOI:10.1007/s12094-008-0150-8 · 2.08 Impact Factor
Show more

Similar Publications